Abstract Treatment options for patients with high-risk acute myeloid leukemia (AML) include high-dose chemotherapy regimens in combination with allogeneic hematopoietic stem cell transplantation, which takes advantage of the donor Tcell-mediated graft-versus-leukemia effect. Together with beneficial responses observed in assays targeted at leukemia-associated antigens (LAA), this encouraged research on cancer vaccines and adoptive cellular therapies in AML. The receptor for hyaluronic acid-mediated motility (RHAMM, CD168) was identified as one of the most promising LAA in AML. Thus far, little is known about in situ expression in leukemic bone marrow blasts or the prognostic role of RHAMM and its interaction partners in AML. We immunohistochemically analyzed the expression and prognostic significance of RHAMM on trephine bone marrow biopsies from 71 AML cases that had been evaluated for cytogenetics and presence of FLT3-internal tandem duplications and NPM1 mutations. Fifty-five patients (77%) were treated with curative intent, while 16 (23%) received the most appropriate supportive care. Twenty of 71 (28%) AML cases were considered RHAMM+. Receiver operating characteristic curves showed significant discriminatory power considering overall survival (OS) in AML patients treated curatively for RHAMM (p=0.015). Multivariable analysis revealed that expression of RHAMM in >5% of leukemic blasts identifies a subgroup of curatively treated cases with adverse OS independent of failures to achieve complete remission. RHAMM not only represents a promising LAA with specific T-cell responses in AML but, if assessed in situ on blasts, also a probable prognostic factor.
Introduction
Acute myeloid leukemias (AML) are neoplastic hematopoietic stem cell disorders characterized by maturation arrest, uncontrolled proliferation, and resistance to apoptosis [1, 2] . Decision making for treatment of AML patients is risk adapted to the World Health Organization (WHO) defined "clinico-pathologic-genetic" entities [3, 4] and further depends on the patient's health status and age. Treatment options range from best supportive care to intensive multiagent chemotherapy alone or high-dose regimens in combination with, primarily, allogeneic hematopoietic stem cell transplantation (allo-HSCT) [5] . In the latter, the graft-versus-leukemia effect suggests that leukemiaspecific T lymphocytes play a major role in attacking and eliminating leukemic cells, thus supporting long-term remission. Along with several observed immunological and clinical responses using assays targeted at leukemiaassociated antigens, these observations encouraged research on cancer vaccines and adoptive cellular therapies in AML [6] [7] [8] . The receptor for hyaluronic acid-mediated motility (RHAMM, CD168) was identified as one of the most promising leukemia-associated antigens in AML [7, [9] [10] [11] [12] [13] . RHAMM has several known functions that vary with respect to its different interaction partners. Interaction with CD44 in the presence of hyaluronic acid plays a role in cellular motility, wound healing, and modification of the Rat sarcoma (Ras)-signaling cascade [14] [15] [16] [17] . Through interactions with signaling cascades related to extracellular signalregulated protein kinase 1/2 (ERK1/2), breast cancer 1 (BRCA1), and BRCA1-associated RING domain 1 (BARD1), RHAMM, alone or in complex with CD44, osteopontin (OPN), and integrins, can promote cancer cell invasion and is essential for tumorigenicity, most likely by oncogenic inhibition of apoptosis [13] [14] [15] [18] [19] [20] [21] [22] [23] . Furthermore, intracellular RHAMM is expressed in a cell cycledependent manner and helps maintaining genomic stability, thus acting as a tumor suppressor [21, 24] . Finally, as a surface molecule on tumor cells, RHAMM has been shown to play an important role in humoral anti-tumor responses [11, 25] . RHAMM has been identified as an important prognostic factor of significance in carcinomas and lymphomas, and also in leukemias [10, [25] [26] [27] [28] [29] [30] [31] [32] [33] . A study of Greiner et al. suggested a probable but statistically not significant favorable prognostic impact of elevated RHAMM mRNA expression in AML [7] .
Along with RHAMM, CD44, a transmembrane glycoprotein, is also a receptor for hyaluronic acid. CD44 can interact with various molecules, like OPN, matrix metalloproteinases, CD95, and also with extracellular RHAMM to promote invasion, angiogenesis, inflammation, and apoptotic resistance [19, 33, 34] . Like RHAMM, CD44 is involved in signaling pathways including cellular sarcoma (c-Src) family kinases and Ras-like family GTPases [34] . CD44 arouse attention in AML research when a monoclonal antibody against this molecule eradicated AML stem cells [35] .
Despite the potentially promising observations on RHAMM in AML, little is known about its in situ expression on bone marrow blasts or its prognostic significance. In addition, there are no data on the expression of its interaction partners, OPN, CD44 and signal transducers, and activators of transcription (STAT), or about its influence on the rate of spontaneous apoptosis in AML. Therefore, we performed immunohistochemical analyses on bone marrow trephine biopsies from a cohort of 71 AML cases to determine the expression and prognostic importance of RHAMM and interacting molecules.
Patients, materials, and methods

Patients
A retrospective cohort of 71 patients with AML was analyzed. All newly diagnosed patients with AML between 2005 and 2007 at the University Hospital Basel, who had been fully evaluated for cytogenetics and molecular markers, including the presence of internal tandem duplications of FMS-like tyrosine kinase 3 (FLT3-ITD) and, in cases with normal cytogenetics, for Nucleophosmin 1 (NPM1) mutations, were included in this study if paraffin blocks of the bone marrow trephine biopsies were adequately preserved for immunohistochemical analyses. All cases were reclassified according to WHO criteria [4] . Clinical and follow-up data were obtained by reviewing the charts. Retrieval of tissue and clinical data were performed according to data safety laws.
Of the 71 patients included in this study, 33 were male (mean age 58, median age 57, range [36] .
Cytogenetic analysis was performed at the Centre Hospitalier Universitaire Vaudois in Lausanne (Unité cytogénétique du cancer). Karyotypes were described according to the International System for Human Cytogenetic Nomenclature [37] . Cases were grouped according to cytogenetics into three risk groups as suggested by Grimwade [38] . FLT3-ITD and NMP1 mutation analysis was performed as described [39] .
Immunohistochemical staining
Paraffin blocks of the 71 bone marrow trephine biopsies were processed in a standardized manner for immunohistochemistry. Eight cases with reactive bone marrow changes (non-hemolytic anemia and thrombocytopenia) served as controls. Table 2 lists the primary antibodies used as well as the incubation and pre-treatment conditions. Visualization of bound secondary antibodies was done by avidin-biotin-peroxidase techniques using either diaminobenzidine (DAB) or aminoethylcarbazole (AEC) as chromogens. Since the staining intensity varied between cases [40, 41] , only the relative proportion (percentage) of positively staining tumor cells was quantified. To study reproducibility of stainings, a second observer reassessed 20% of cases.
Statistics
Statistical analyses were performed using SPSS version 15.0 (SPSS, Chicago, IL). Incomplete data were not excluded from the tests. The degree of agreement between the observers for the quantitative immunohistochemical values was evaluated by intra/interclass correlation coefficients using the Cronbach's alpha analysis. The Spearman's test was used to analyze relationships between the markers. Only correlation coefficients >0.300 or <−0.300 were further considered. The Fisher's exact test was used to analyze differences in distribution of case numbers between groups. Mann-Whitney or Kruskal-Wallis tests were applied as appropriate to assess differences of means between groups. The prognostic performance of the variables and determination of optimal cut-off values was established by receiver operating characteristic (ROC curves plotting sensitivity versus 1-specificity with special consideration of the respective area under the ROC (AUROC)). The optimal cut-off point was calculated using Youden's index (Y), denoting Y = sensitivity + specificity − 1, since this method can be applied to find the optimal cut-off value with the highest sensitivity and specificity when there is no particular requirement on sensitivity and/or specificity [42] . OS was analyzed by the Kaplan-Meier method and compared by the log-rank test in univariable modus and by the Cox' regression analysis in multivariable modus. Only factors that were determined to be of at least trend prognostic significance in the univariable modus (p<0.1) were entered into the multivariable analysis. Statistical significance was defined as p<0.05 and corrected for multiple testing, when necessary. Two-sided tests were used throughout.
Results
Response to therapy and clinical outcomes
The average follow-up time was 16.7 months (median 10; range 0−62). Within this time, 32 patients died. Most of the patients (n=55) were treated with curative intent (chemotherapy alone: n=25; intensive chemotherapy followed by autologous HSCT: n=4; intensive chemotherapy followed by allo-HSCT: n=26). Sixteen patients did not qualify for intensive treatment. Five were given hydroxyurea and the others received best supportive care. The mean OS of patients treated without intention to cure was 4.4 months and the median 1.3 months, while the OS of patients treated Cut-off scores were determined by ROC curves: panCD44 >5%, RHAMM >5%, osteopontin (OPN) >25%, active caspase-3 >0.5% FACR failure to achieve complete remission,
The risk groups among AML, not otherwise specified were defined according to Grimwade et [4, 38] , patients' age, regimen composition nor any of the studied phenotypic and genetic markers. Failure to achieve complete remission was a prognostic factor for OS (p=0.039), while patients' age, gender, leukemia subtype were not, yet the KaplanMeier survival curves indicated poorer outcomes for elderly patients and patients with therapy-related AML as well as such with complex karyotypes. These observations were particularly due to the fact that patients treated with curative intent were treated in different ways according to their "clinico-pathologic-genetic" risk and patients being at risk were treated in a more intensive way, which probably evened outcomes (Table 1) .
One third of AML express cytoplasmic/membranous RHAMM in approximately 20% of blasts Assessment of RHAMM and active caspase-3 expression was highly reproducible (average interobserver correlation coefficient α=0.92 and 0.89, respectively), and that of panCD44 and OPN was good (α=0.82 and 0.79, respectively). Except for 10 AML cases that were not assessable for active caspase-3 quantification, all cases were evaluable by immunohistochemical analysis. In reactive bone marrows, panCD44 was expressed in erythropoietic precursors, as expected [43] , and the same was found with OPN. RHAMM was detectable in single myelo-/ monopoietic precursors and mature mononuclear cells, as formerly shown [29, 44] . Active caspase-3 stained two to 16 apoptotic bodies per 0.283 mm 2 , especially in areas rich in erythropoiesis. Qualitative impression of the various antibody staining patterns can be extracted from Fig. 1a and b .
Compared to controls, AML cases showed primarily qualitative staining differences, expressing the respective molecules in different cell populations. PanCD44 was strongly expressed in a mean of 38% of AML blasts in the 16 positive cases (cut-off score >5%), RHAMM in a mean of 19% of AML blasts in the 20 positive cases (cut-off score >5%) and OPN in 52% of AML blasts in the 35 positive cases (cut-off score >25%). The sub-cellular localization of stainable RHAMM was predominantly cytoplasmic. In AML cases with blasts negative for the respective marker, there were few erythropoietic or mononuclear cells remaining, occasionally expressing panCD44, OPN, or/and RHAMM, which served as internal positive control. Active caspase-3 stained 0 to 29 apoptotic bodies per 0.283 mm 2 , which were morphologically attributable to leukemic blasts. Quantitative immunohistochemical data are shown in Table 1 . Qualitative impression of the various antibodies' staining patterns can be extracted from Fig. 1c-f .
Expression of RHAMM in AML correlates with panCD44, pSTAT3, and pSTAT5, and with the spontaneous apoptotic activity Expression of the analyzed markers was correlated with each other and to known clinical and pathological parameters previously determined on the study collective, such as WHO leukemia subtype, patient age and gender, lack of complete remission, expression of pSTAT1, pSTAT3, and pSTAT5, and presence of FLT3-ITD and NPM1 mutations [39] . RHAMM correlated with expression of panCD44 (ρ=0.560), of pSTAT3 and pSTAT5 (ρ=0.521 and 0.347, respectively) and with spontaneous apoptosis as determined by the expression of active caspase-3 (ρ=0.321). The correlations of RHAMM and panCD44 as well as pSTAT3 and pSTAT5 expression were also observable in AML with recurrent genetic aberrations and AML, not otherwise specified; in addition in AML with normal karyotype and noncomplex abnormalities according to Grimwade [38] , presence of FLT3-ITD correlated with failures to achieve complete remission (ρ = 0.504). In AML with myelodysplasia-related changes RHAMM correlated with pSTAT1 expression in blasts (ρ=0.565), while this correlation was weaker (ρ=0.288) in the AML collective as a whole. There were no correlations between the studied markers and NPM1 mutation status.
RHAMM is a WHO subtype-, age-, treatment type-, and response to treatment-independent negative prognostic factor in AML Patients treated with curative intent (n=55) and those receiving best supportive care (n=16) were analyzed separately to exclude treatment effect bias. Of the markers analyzed, ROC curve-based analysis showed significant discriminatory power for survival of curatively treated AML patients only for RHAMM (AUROC = 0.721, p=0.015; Fig. 2a) . In a further step, this was linked to survival by the Kaplan-Meier method and compared by the log-rank test using the cut-off score suggested by ROC, i.e., >5% blasts; the expression of RHAMM showed a significant negative prognostic effect (Fig. 2b ) that was particularly evident in patients who failed to achieve complete remission after induction treatment ( Fig. 3a and b) . Importantly, expression of RHAMM in patients who did or did not achieve complete remission was similar, and the lack of complete remission did not correlate to any of the above-mentioned clinical or pathological parameters. Analyzed with respect to the WHO entities and the Grimwade's cytogenetic prognostic groups [38] , the negative prognostic effect of RHAMM was apparent in the Kaplan-Meier curves in AML with recurrent genetic aberrations, in AML, not otherwise specified, in the favorable risk group AML and in AML with normal karyotypes and other noncomplex abnormalities (intermediate risk group) according to Grimwade. Except for AML with normal karyotypes and other noncomplex abnormalities (intermediate risk group), where statistical significance was reached (p=0.029) patient numbers were too low in any of the groups to draw statistical conclusions. Considering the type of curative treatment regimens, this effect remained significant only for patients treated with multiagent chemotherapy (p=0.031), and not with high-dose regimens with HSCT (p=0.119). In a multivariable model, expression of RHAMM turned out to be a negative prognostic factor independent of failure to achieve complete remission in curatively treated AML (p=0.002, relative risk 5.38, 95% confidence interval 1.75-16.49 for RHAMM; p=0.017, relative risk 4.23, 95% confidence interval 1.29-13.78 for failure to achieve complete remission). 
Discussion
Our study is the first histopathology-based qualitative and quantitative examination of the expression of RHAMM and its partners in AML patients by immunohistochemistry on trephine bone marrow biopsies. Expression of RHAMM in >5% of leukemic blasts identified a subgroup of AML patients (treated curatively) with poor prognoses independent of AML WHO subtype or age. This effect was particularly pronounced in patients who failed to achieve complete remission after induction therapy. Thus, our results considerably extend previous data on RHAMM in AML, showing that RHAMM not only represents a promising leukemia-associated antigen, similar to the preferentially expressed antigen in melanoma and the carbonic anhydrase IX (G250), with specific T-cell responses that suggest the possibility of tumor vaccination [11, 13] , but also a prognostic tumor-related factor with a among the patients who failed to achieve complete remission four out of 20 RHAMM-negative patients died, mean survival 47 months, median not reached, compared to all six RHAMM-positive patients, mean survival 10 months, median 9 months, p=0.001 for (b) particular prognostic significance for patients failing to achieve complete remission after induction treatment. The latter might be of special interest since there are no established prognostic factors for AML in patients who failed to achieve complete remission. RHAMM expression has been shown to be of prognostic importance in hematological neoplasia like B-cell chronic lymphocytic leukemia, plasma cell myeloma, and diffuse large B-cell lymphoma [10, [27] [28] [29] . The biological background of the observed prognostic effects of RHAMM is not known. Because it is, on the one hand, a surface receptor molecule, and on the other, a functional intracellular protein, RHAMM plays different roles that vary with respect to its numerous interaction partners. Together with CD44, RHAMM promotes cellular motility, wound healing, and the Ras-signaling cascade [15] [16] [17] . Through interactions with signaling related to ERK1/2, BRCA1 and BARD1, RHAMM, alone or in complexes with CD44, OPN, and integrins, RHAMM can be tumorigenic, most likely by inhibition of apoptosis [13] [14] [15] [18] [19] [20] [21] [22] [23] . In addition, intracellular RHAMM helps maintaining genomic stability [21, 24] . Finally, as a surface molecule on tumor cells, RHAMM has been shown to play an important role in humoral anti-tumor responses [11, 25] .
A former study of Greiner et al. suggest a possible yet not statistically significant (p=0.284) favorable prognostic impact of RHAMM in AML [7] . These authors studied gene expression levels of tumor-associated antigens from peripheral blood and bone marrow samples utilizing mRNA quantification of extracts from frozen mononuclear cells. The probable positive prognostic effect of RHAMM was attributed to anti-leukemic activity of the immune system represented by killing residual tumor cells expressing such tumor-associated antigens. The discrepancy in the observed prognostic impact of RHAMM between our study and that of Greiner et al. might be due to the different methodologies employed to determine RHAMM expression, i.e., mRNA quantification and in situ analysis of blast counts with surface/cytoplasmic protein expression. This could reflect different RHAMM functions as an oncogene (surface, cytoplasmic protein), a tumor-suppressor gene (nuclear protein) or leukemia-associated antigen (surface and extracellular protein). Lastly, considering the controversies on the prognostic impact of expression levels of another leukemia-associated antigen, WT1, in the study of Greiner et al. and previous studies [7, 45, 46] , and the minor, if any, statistical significance of the gene expression of all studied leukemia-associated antigens in the former study, the in situ approach chosen in our study might more ostensibly mirror the oncogenic function of RHAMM in AML. In our AML collective, RHAMM was predominantly cytoplasmically expressed in a proportion of blasts, and closely correlated with expression of CD44 and pSTAT3 and pSTAT5 as well as with spontaneous leukemia apoptosis, but did not correlate with OPN. This indicates that RHAMM is probably not constitutively expressed by all blasts, and that its observed effects might be related to the interference of OPN-independent RHAMM with AML cell signaling or locomotion, and rather not with its antiapoptotic functions.
In summary, beyond being a promising leukemiaassociated antigen in AML, consideration of RHAMM surface/cytoplasmic expression in blasts may allow identification of a subgroup of curatively treated patients with poor prognosis independent of AML WHO subtype, especially in patients who failed to achieve complete remission after induction therapy, which might merit further evaluation. 
